Research programme: monoclonal antibody 1F7 - Immune Network/InNexus Biotechnology

Drug Profile

Research programme: monoclonal antibody 1F7 - Immune Network/InNexus Biotechnology

Alternative Names: 1F7

Latest Information Update: 04 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Developer Immune Network; InNexus Biotechnology
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 14 Jun 2002 InNexus has acquired a sublicense from Immune Network to develop monoclonal antibody1F7
  • 25 Jan 2002 Immune Network has entered into a research collaboration with the University of British Columbia
  • 16 Jan 2002 A study has been added to the Viral Infections immunogenicity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top